Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond E, Perez E, Bryant J, Suman V, et al. Tastuzumab Plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab Plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond E, Perez E, Bryant J, Suman V, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Increased use of medical technology, like colonoscopy and sigmoidoscopy for colon cancer screening, could save $178.2 billion between 2010 and 2035.  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets late-stage metastatic melanoma. The medicine contains a gene encoding antigen that may be able to…  
  • Thousands of potential cancer medicines in development
     
  • Following the current path, the colon cancer incidence rate will increase by 31.8% between 2003 and 2023 (447,000 people). If an alternative path is taken, there will be 17.7% (79,000…  
  • Since Congress passed the National Cancer Act in 1971, the percentage of the U.S. population living with, through, or beyond a cancer diagnosis has more than tripled.